Trial Profile
CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Cancer; Graft-versus-host disease
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 01 Sep 2010 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
- 01 May 2008 Status changed to suspended as reported by ClinicalTrials.gov
- 18 Jan 2007 Interim results have been reported.